Evidence map›Paper›PMID 28108439›Full record

ArticleBMJ case reports2017

De novo 2p16.1 microdeletion with metastatic esophageal adenocarcinoma.

Don Chamil Codipilly, Ralitza H Gavrilova, Eric G Tangalos

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Utility of clinical exome sequencing in a complex Emirati pediatric cohort.Computational and structural biotechnology journal · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Don Chamil CodipillyDepartment of Internal Medicine, Mayo Clinic Minnesota, Rochester, Minnesota, USA.ORCID http://orcid.org/0000-0003-3197-0539
Ralitza H GavrilovaDepartment of Clinical Genomics and Neurology, Mayo Clinic Minnesota, Rochester, Minnesota, USA.
Eric G TangalosDepartment of Primary Care Internal Medicine, Mayo Clinic Minnesota, Rochester, Minnesota, USA.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microdeletions involving chromosome 2p15-16.1 are a rare genetic abnormality and have been reported in 18 separate patients, mainly children, since 2007. This microdeletion syndrome is characterised by a heterogeneous expression of intellectual impairment, dysmorphic facies, musculoskeletal abnormalities and potential neurodevelopmental anomalies. We report the first case of natural progression in an adult patient who died at a young age of metastatic esophageal adenocarcinoma. Important learning points include the variable phenotypic expression of this microdeletion syndrome and the fact that clinicians must be thorough in investigating objective discrepancies in patients who cannot endorse classical symptoms.

Indexed as

Chromosome DeletionAdenocarcinomaAdultBone NeoplasmsChromosome DisordersChromosomes, Human, Pair 2EpilepsyEsophageal NeoplasmsEsotropiaFaciesGait Disorders, NeurologicHumansIntellectual DisabilityMaleMicrocephalyMuscle Hypotonia

Identifiers

PMID28108439
PMCPMC5256579
OpenAlexW2575789925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.